Skip to main content
BEIJING HOTGEN BIOTECH CO., LTD. logo

BEIJING HOTGEN BIOTECH CO., LTD. — Investor Relations & Filings

Ticker · 688068 ISIN · CNE100003P82 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 880 across all filing types
Latest filing 2026-05-25 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 688068

About BEIJING HOTGEN BIOTECH CO., LTD.

https://www.hotgenbiotech.com/

Beijing Hotgen Biotech Co., Ltd. specializes in the research, development, and manufacturing of in vitro diagnostic (IVD) products. The company utilizes advanced technology platforms, including Up-converting Phosphor Technology (UPT), chemiluminescence immunoassay (CLIA), and molecular diagnostics. Its product portfolio encompasses a wide range of rapid diagnostic kits and automated analyzers designed for the detection of infectious diseases, cardiovascular conditions, hepatic fibrosis, and inflammatory markers. Hotgen Biotech is recognized for its contributions to global public health through the provision of high-sensitivity antigen and antibody testing solutions. The company serves clinical laboratories, hospitals, and point-of-care settings, focusing on delivering accurate, efficient, and user-friendly diagnostic tools to improve patient outcomes and disease management.

Recent filings

Filing Released Lang Actions
北京热景生物技术股份有限公司关于以集中竞价交易方式回购股份的回购报告书
Transaction in Own Shares Classification · 91% confidence The document is a formal share repurchase report (“回购报告书”) by Beijing HotGen Biotech, detailing board resolutions, repurchase amount, price range, timing, funding source, and implementation procedures for buying back its own shares. This is clearly a transaction in own shares, matching the definition of POS (Transaction in Own Shares).
2026-05-25 Chinese
北京热景生物技术股份有限公司自愿披露子公司创新药SGC001注射液新增适应症临床试验申请获得《受理通知书》的公告
Regulatory Filings Classification · 87% confidence The document is a voluntary corporate announcement by Beijing HotGen Biotech concerning its subsidiary’s clinical trial application acceptance notice for a new indication of its drug SGC001. It contains no financial statements or data, nor is it a report publication notice. It is a general regulatory announcement regarding drug approval proceedings. Therefore, it fits the Regulatory Filings (RNS) category.
2026-05-25 Chinese
北京热景生物技术股份有限公司关于以集中竞价交易方式首次回购公司股份的公告
Transaction in Own Shares Classification · 90% confidence The document is an official announcement by Beijing Rejing Biotech Co., Ltd. detailing the progress of its share repurchase plan (centralized bidding transactions), including dates, amounts, number of shares repurchased, prices, and regulatory references. This clearly describes the company’s own share buyback activity, matching the definition for Transaction in Own Shares (Code: POS).
2026-05-25 Chinese
北京热景生物技术股份有限公司关于提前终止回购股份出售计划暨回购股份出售结果的公告
Transaction in Own Shares Classification · 95% confidence The document is an official announcement regarding the company’s sale of shares previously repurchased under its share buyback program, including quantities, prices, plan termination, and compliance details. This matches the definition of a Transaction in Own Shares (POS).
2026-05-21 Chinese
北京热景生物技术股份有限公司关于以集中竞价交易方式回购股份方案的公告
Transaction in Own Shares Classification · 92% confidence The document is an official announcement by the company’s board regarding a share repurchase scheme via centralized bidding, with details on the repurchase amount, price, duration, funding source, board resolutions, and legal authorizations. This constitutes a Transaction in Own Shares (share buyback) filing.
2026-05-21 Chinese
北京热景生物技术股份有限公司第四届董事会第十二次会议决议公告
Transaction in Own Shares Classification · 85% confidence The document is a “董事会会议决议公告” – a board resolution approving a share repurchase plan (“回购股份方案”). It is not a management change (MANG) nor a simple notice of a report. It specifically concerns the board’s approval of a share buyback proposal, which falls under “Transaction in Own Shares” (POS).
2026-05-21 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.